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OBJECTIVE: The primary objective of this study was to
estimate survival functions and natural history of patients
67
infected with human immunodeficiency virus (HIV) who
were using antiretroviral medication with a protease in-
hibitor versus those who were under treatment protocols
without protease inhibitors.
METHODS: Data used in this study were collected using
two sources: expert physician surveys and the literature
search. The transition was obtained from both sources.
The fundamental matrix solution of a Markov chain
model was used to estimate survival functions and natu-
ral history profiles for HIV-infected patients. The re-
search was conducted from the perspective of a managed
care organization.
RESULTS: The median survival time of patients with ini-
tial CD 4 cell counts above SOO/mm3 for the drug regimen
without a protease inhibitor was estimated to be 8.6
years compared to 12.9 years for patients taking a combi-
nation therapy with one protease inhibitor. Similar re-
sults were obtained for patients with various CD 4 cell
counts at the initiation of therapy. A series of natural his-
tory estimates quantified the progress of disease which
showed that the use of protease inhibitors significantly
reduced the rate of progression of the disease.
CONCLUSION: Results from the Markov chain analysis
suggested that protease inhibitors significantly improved
overall survival of HIV-infected patients by deterring the
progression of disease and onset of various opportunistic
infections.
PIC2
SOCIOECONOMIC RELEVANCE OF INPATIENT
TREATMENT OF INTRA-ABDOMINAL
INFECTIONS WITH TAZOBACTAMI
PIPERACILLIN 0.5 g/4.0 g IN COMPARISON
WITH IMIPENEM/CILASTATIN
Bruchhausen Y. Rappenhoner B. Kremer B. Rychlik R
Institute of Empirical Health Economics, Odenthal, Germany
Imipenem/Cilastatin and TazobactamJPiperacillin are two
of the most preferred antibiotics to treat intra-abdominal
infections. In a retrospective analysis the cost structure
was established.
OBJECTIVE: The purpose of this study was to analyse
the medical and economic relevance of above alternative
antibiotic treatments based on a compariative multicentre
clinical study. The comparison of costs and benefits was
made on the basis of a cost-effectiveness analysis.
METHODS: A one-patient model was considered first. In
the one-patient model (Markov model) three states were
constructed: (1) successful therapy, (2) failed therapy be-
cause of adverse drug reactions, and (3) failed therapy be-
cause of lack of efficacy. Health care costs included in the
model were all medical costs (hospitalization, drug costs,
therapy of adverse drug reactions, etc.) and indirect costs
(absence from workplace). Indirect costs are calculated
with the human capital approach. Success was defined as
the clinical curing and improvement rate. The success
rate of the therapy with Tazobactam/Piperacillin was
